Answers are grounded in this paper and cite their sources.
Gastroesophageal reflux disease (GERD) is among the most prevalent disorders of the upper gastrointestinal tract worldwide. Although proton pump inhibitor (PPI) therapy is the standard first-line treatment, up to 40% of patients experience persistent symptoms despite adequate therapy. Endoscopic anti-reflux mucosal interventions (ARMIs), which induce scar-mediated tightening of the gastroesophageal junction through targeted mucosal resection or ablation at the gastric cardia, have emerged as minimally invasive alternatives for patients with PPI-dependent or refractory GERD. This review comprehensively summarizes the pathophysiological rationale, procedural approaches, clinical outcomes, adverse events, and comparative evidence for the principal ARMI techniques, including anti-reflux mucosectomy (ARMS), anti-reflux mucosal ablation (ARMA), peroral endoscopic cardial constriction, and anti-reflux mucoplasty. Meta-analyses demonstrate clinical response rates of approximately 80% for ARMS, while standardization of the butterfly-shaped resection pattern has reduced stricture rates. ARMA provides symptom control comparable to ARMS with fewer complications, although long-term comparative data remain limited. Careful patient selection, systematic preprocedural evaluation, and postprocedural follow-up are essential for optimizing clinical outcomes. Randomized controlled trials comparing ARMIs with laparoscopic and transoral incisionless fundoplication are needed to define their role in the GERD treatment algorithm.
No takes yet. Share an insight, caveat, or question.
Gwang Ha Kim (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: